Hypertension is a leading risk factor for cardiovascular morbidity and mortality. Despite the
widespread availability of both pharmacological and lifestyle therapeutic options, blood …

Abstract The US Food and Drug Administration has approved renal denervation (RDN) as a
new treatment option for hypertension (HT) because it not only has antihypertensive effects …

Renal denervation (RDN) is a minimally invasive, endovascular catheter-based procedure
using radiofrequency, ultrasound, or alcohol-mediated ablation to treat resistant …

Abstract William Bayliss and Ernest Starling are not only famous as pioneers in
cardiovascular physiology, but also responsible for the discovery of the first hormone (from …

In 2023, there were several new developments in the field of cardionephrology with potential
impact on the care of patients with dual burden of heart and kidney disease. With new drugs …

The US Food and Drug Administration recently approved 2 renal denervation (RDN)
systems, the ultrasound-based RDN (uRDN, Recor Paradise) and the multipolar …

Renal artery denervation has re-emerged as a potential therapeutic option for patients with
hypertension, especially those resistant to conventional pharmacotherapy. This …

Hypertension (HTN) is one of the largest contributors to cardiovascular (CV) morbidity and
mortality in the USA and is estimated to affect 47% of the US population; however, recent …

Abstract Treatment-resistant hypertension (TRH) is diagnosed when blood pressure remains
above 140/90 mmHg systolic/diastolic despite lifestyle changes and the use of at least three …

Azizi M, Sharp ASP, Fisher NDL, Weber MA, Lobo MD, Daemen J, Lurz P, Mahfoud F,
Schmieder RE, Basile J, et al; RADIANCE Investigators. Patient-level pooled analysis of …